Treatment of relapsed CBCC, CC and LPIC lymphoma with FCM chemotherapy alone or in combination with the monoclonal anti CD 20 antibody rituximab followed by anti-CD 20 maintenance or observation only
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Cyclophosphamide; Fludarabine; Mitoxantrone; Rituximab
- Indications Follicular lymphoma; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- 07 May 2021 Biomarkers information updated
- 27 Jul 2007 The expected completion date for this trial is now 1 Dec 2008.
- 22 Nov 2006 New trial record.